ReviewHematology. American Society of Hematology. Education Program2024
Practical guide to the diagnosis and management of heparin-induced thrombocytopenia.
Review in Hematology. American Society of Hematology. Education Program, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Clinical practice guideline for renal replacement therapy in critically ill patients with acute kidney injury (2026 edition).Journal of intensive medicine · 2026Article
- Real-World Performance of the STic Expert HIT Kit and the Diagnostic Dilemma of Borderline Results in Heparin Induced Thrombocytopenia.International journal of laboratory hematology · 2026Article
- Serotonin Signaling and Vascular Reactivity in Cardiometabolic Disease and Cardiac Surgery.Cells · 2026Review
- Analysis of drug-induced pulmonary embolism risk based on the Food and Drug Administration Adverse Event Reporting System database.Journal of thoracic disease · 2026Article
- [Analysis of Clinical Characteristics and Diagnostic Indicators in Patients With Heparin-induced Thrombocytopenia After Cardiac Surgery].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026Article
- Heparin Anticoagulant Therapy and Its Monitoring.Biomolecules · 2026Review
- Low-molecular-weight heparins in atrial fibrillation: clinical scenarios, limitations, and future perspectives.Frontiers in pharmacology · 2026Review
- The hidden threat: understanding anti-PF4 disorders without proximate heparin exposure.Frontiers in immunology · 2026Review
- Spinal intradural hematoma after intrathecal drug delivery system implantation in a patient with possible heparin-induced thrombocytopenia: a case report.Frontiers in oncology · 2026Article
- Clinical pharmacist-guided management of heparin-induced thrombocytopenia with thrombosis after hip hemiarthroplasty: a case report.Frontiers in cardiovascular medicine · 2026Article
- Inter-Observer Agreement and Laboratory Correlation of the 4T Scoring Model for Heparin-Induced Thrombocytopenia: A Single-Center Retrospective Study and Literature Review.Journal of clinical medicine · 2025Article
- Anti-PF4 disorders: Pathogenesis, diagnosis and treatment.British journal of haematology · 2025Review
- Article
- Low-molecular-weight heparin-induced thrombocytopenia with multisite embolism: successful management with argatroban and dabigatran - a case report and literature review.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heparin-induced thrombocytopenia (HIT) is an immune reaction to heparin associated with thrombocytopenia, thrombotic risk, and a high risk of morbidity and mortality. Given the frequent use of heparin and the common occurrence of thrombocytopenia in hospitalized patients, the diagnosis and management of HIT is a recurrent challenge in everyday inpatient care. This article presents practical guidance and tools to support the individual clinician providing evidence-based care to patients with suspected or confirmed HIT. The optimal diagnostic evaluation requires the stepwise use of risk-stratification tools and laboratory assays. Management requires the selection and use of nonheparin anticoagulation in these complex patients with both increased thrombotic risk and possible concurrent increased bleeding risk due to thrombocytopenia. Each step in the diagnostic and management process has important nuances and complexities, many of which vary based on patient characteristics and institutional resources. Given the many challenges of HIT care, truly practical management is best achieved when tools are implemented to support the delivery of consistent, high quality, and cost-effective care across health systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.